Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
School of Public Health, China Medical University, Shenyang, Liaoning Province, China.
Medicine (Baltimore). 2023 Feb 17;102(7):e32945. doi: 10.1097/MD.0000000000032945.
RNA N6-methyladenosine (m6A) regulators are essential for a variety of biological functions, such as early development, viral infections, and cancer. However, their roles in Alzheimer disease (AD) are still not very clear. Here, 16 significant m6A regulators were identified using difference analysis between AD patients and non-demented controls based on the GSE132903 dataset from the Gene Expression Omnibus database. Using these 16 m6A regulators, a nomogram model was established to predict the prevalence of AD. We found that patients could obtain a good clinical benefit based on this model. In addition, we revealed 2 distinct m6A patterns and 2 distinct m6A gene patterns in AD and demonstrated their prognostic and risk assessment significance. This present work comprehensively evaluated the functions of m6A regulators in the diagnosis and subtype classification of AD. These results suggested they have potential prognostic and risk assessment significance in AD.
RNA N6-甲基腺苷(m6A)调节剂对于多种生物学功能至关重要，例如早期发育、病毒感染和癌症。然而，它们在阿尔茨海默病(AD)中的作用尚不清楚。在这里，我们使用来自基因表达综合数据库(Gene Expression Omnibus database)的 GSE132903 数据集，通过 AD 患者与非痴呆对照之间的差异分析，鉴定了 16 个显著的 m6A 调节剂。利用这 16 个 m6A 调节剂，建立了一个列线图模型来预测 AD 的患病率。我们发现患者可以根据这个模型获得良好的临床获益。此外，我们在 AD 中揭示了 2 种不同的 m6A 模式和 2 种不同的 m6A 基因模式，并证明了它们的预后和风险评估意义。本研究全面评估了 m6A 调节剂在 AD 的诊断和亚型分类中的功能。这些结果表明它们在 AD 中具有潜在的预后和风险评估意义。
